AVENUE THERAPEUTICS, INC. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. NOTABLE10-QAVENUE THERAPEUTICS, INC.ATXIMay 8

   Quarterly report

2. NOTABLE10-KAVENUE THERAPEUTICS, INC.ATXIMar 30

   Annual report

3. ROUTINE8-KAVENUE THERAPEUTICS, INC.ATXIFeb 23

   Current report

4. ROUTINESCHEDULE 13G/AAVENUE THERAPEUTICS, INC.ATXIFeb 17

   Ownership stake disclosure by Ikarian Capital, LLC (amended)

   Ikarian Capital, LLC, filed by

5. NOTABLESCHEDULE 13D/AAVENUE THERAPEUTICS, INC.ATXIJan 6

   Ownership stake disclosure by Fortress Biotech, Inc. (amended)

   Fortress Biotech, Inc., filed by

6. ROUTINE4AVENUE THERAPEUTICS, INC.ATXIJan 6

   Fortress Biotech, Inc., insider filing for ATXI

   Fortress Biotech, Inc., reporting

7. ROUTINE8-KAVENUE THERAPEUTICS, INC.ATXIDec 31, 2025

   Current report

8. ROUTINEEFFECTAVENUE THERAPEUTICS, INC.ATXIDec 17, 2025

   Registration declared effective

9. ROUTINEPOS AMAVENUE THERAPEUTICS, INC.ATXIDec 15, 2025

   POS AM filing

10. ROUTINERWAVENUE THERAPEUTICS, INC.ATXIDec 15, 2025

    RW filing

11. ROUTINEDEF 14AAVENUE THERAPEUTICS, INC.ATXIDec 5, 2025

    Proxy statement

12. NOTABLE8-KAVENUE THERAPEUTICS, INC.ATXINov 19, 2025

    AVENUE THERAPEUTICS, INC. reported: Shareholder Director Nominations.

    • Item 5.08 Shareholder Director Nominations.
    • Item 8.01 Other Events.
13. NOTABLE10-QAVENUE THERAPEUTICS, INC.ATXINov 13, 2025

    Avenue Therapeutics, Inc. (ATXI) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational status.

14. ROUTINE8-KAVENUE THERAPEUTICS, INC.ATXINov 12, 2025

    Current report

Older filings on EDGAR